{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T11:52:54Z","timestamp":1790941974725,"version":"4.1.0"},"reference-count":44,"publisher":"Wiley","issue":"15","license":[{"start":{"date-parts":[[2009,5,26]],"date-time":"2009-05-26T00:00:00Z","timestamp":1243296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2009,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>Beyond the usual regimens based on streptozocin and doxorubicin or 5\u2010fluorouracil, no second\u2010line therapy of metastatic neuroendocrine tumor has gained wide acceptance. Gemcitabine and oxaliplatin are generally well tolerated and have shown activity against a wide range of malignancies. The authors assessed the efficacy of gemcitabine\u2010oxaliplatin combination (GEMOX) in the treatment of patients with metastatic neuroendocrine tumors.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>Twenty consecutive patients with progressive disease were treated with GEMOX, in most cases after failure of other chemotherapy regimens (median = 2). Patients were followed for evidence of toxicity, response, and survival. Two patients were chemotherapy\u2010naive at treatment initiation and were excluded from the efficacy analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>Toxicity was manageable overall; however, 6 (30%) patients had to discontinue treatment because of oxaliplatin\u2010induced neurotoxicity (grade 2). Three (17%) of 18 patients had a partial response, median progression\u2010free survival was 7.0 months, and median overall survival was 23.4 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>Gemcitabine\u2010oxaliplatin combination shows interesting activity and is well tolerated in pretreated patients with neuroendocrine tumors. Cancer 2009. \u00a9 2009 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.24384","type":"journal-article","created":{"date-parts":[[2009,5,26]],"date-time":"2009-05-26T22:54:46Z","timestamp":1243378486000},"page":"3392-3399","source":"Crossref","is-referenced-by-count":51,"title":["Gemcitabine and oxaliplatin combination chemotherapy for metastatic well\u2010differentiated neuroendocrine carcinomas"],"prefix":"10.1002","volume":"115","author":[{"given":"Philippe A.","family":"Cassier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Eymard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Ardisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"Perol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Paillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Alain","family":"Chayvialle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Yves","family":"Scoazec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Hervieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine Lombard","family":"Bohas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,5,26]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1677\/erc.0.0110001"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm552"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.4377"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-006-0250-1"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-007-0452-1"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1159\/000085237"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198011203032101"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1984.2.11.1255"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199202203260804"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.616"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.2553"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.7858"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.9020"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.6.2403"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20466"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.16.2938"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.023"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa073149"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh351"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1385\/IJGC:36:1:055"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-006-0306-6"},{"key":"e_1_2_6_23_2","first-page":"15502","article-title":"A phase II study of capecitabine, oxaliplatin and bevacizumab for metastatic or unresectable neuroendocrine tumors: preliminary results [abstract]","volume":"26","author":"Kunz PL","year":"2008","journal-title":"ASCO Meeting Abstr."},{"key":"e_1_2_6_24_2","first-page":"15545","article-title":"Phase II trial of FOLFOX plus bevacizumab in advanced, progressive neuroendocrine tumors [abstract]","volume":"26","author":"Venook AP","year":"2008","journal-title":"ASCO Meeting Abstr."},{"key":"e_1_2_6_25_2","volume-title":"World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of Endocrine Organs","author":"DeLellis RA","year":"2004"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0046-8177(98)90047-8"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.04.024"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2003.09.035"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf064"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1012569909313"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2003.11.016"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010415)91:8<1543::AID-CNCR1163>3.0.CO;2-N"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1081\/CNV-200029058"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.COC.0000054535.19808.F4"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2053"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.6046"},{"key":"e_1_2_6_38_2","first-page":"4044","article-title":"A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors","volume":"24","author":"Kulke MH","year":"2006","journal-title":"ASCO Meeting Abstr."},{"key":"e_1_2_6_39_2","first-page":"14023","article-title":"Temozolomide\/capecitabine therapy for metastatic neuroendocrine tumors of the pancreas. A retrospective review","volume":"24","author":"Isacoff WH","year":"2006","journal-title":"ASCO Meeting Abstr."},{"key":"e_1_2_6_40_2","first-page":"4612","article-title":"First\u2010line treatment of metastatic pancreatic endocrine carcinoma with capecitabine and temozolomide","volume":"26","author":"Strosberg JR","year":"2008","journal-title":"ASCO Meeting Abstr."},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603419"},{"key":"e_1_2_6_42_2","first-page":"4504","article-title":"MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): a Phase II Consortium (P2C) study","volume":"25","author":"Hobday TJ","year":"2007","journal-title":"ASCO Meeting Abstr."},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.6374"},{"key":"e_1_2_6_44_2","first-page":"4008","article-title":"A phase 2 study to evaluate the efficacy and safety of SU11248 in patients (pts) with unresectable neuroendocrine tumors (NETs)","volume":"23","author":"Kulke M","year":"2005","journal-title":"ASCO Meeting Abstr."},{"key":"e_1_2_6_45_2","first-page":"4503","article-title":"Phase II study of RAD001 (everolimus) and depot octreotide (sandostatin LAR) in advanced low grade neuroendocrine carcinoma (LGNET)","volume":"25","author":"Yao JC","year":"2007","journal-title":"ASCO Meeting Abstr."}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.24384","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.24384","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T09:18:04Z","timestamp":1760260684000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.24384"}},"subtitle":["A single\u2010center experience"],"short-title":[],"issued":{"date-parts":[[2009,5,26]]},"references-count":44,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["10.1002\/cncr.24384"],"URL":"https:\/\/doi.org\/10.1002\/cncr.24384","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5,26]]}}}